ClinicalTrials.gg
Not yet recruitingNCT07947446CHUCOLATEUpdated Nov 19, 2026

CHUCOLATE: Current Knowledge and Prevalence of LATE-NC in Geriatric Memory Clinics at a Memory Center in Lorraine

An observational study in Alzheimer s Disease, TDP-43 Proteinopathies and MCI, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Alzheimer Disease by Central Hospital, Nancy, France — 9 open to participants now, 9 under way, none of them phase 3. Alzheimer Disease · Central Hospital, Nancy, France.

Started
2026
with 1 other
Observational
8 of 17
5 open now
Registered
17th of 17
by date

Among the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France, this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 17th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

9 of the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alzheimer Disease by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

LATE syndrome (Limbic-predominant Age-related TDP-43 Encephalopathy) is a neurocognitive disorder associated with TDP-43 proteinopathy, whose clinical presentation-a hippocampal amnestic syndrome-is similar to that of Alzheimer's disease. There are no specific markers to differentiate between the two, other than the exclusion of Alzheimer's biomarkers (AB), a criterion limited by the possibility of comorbidity. In the era of anti-amyloid therapies, it is crucial to differentiate between them in order to appropriately offer these therapies to patients. The clinical diagnosis of LATE is therefore of great importance. A pattern specific to LATE has been described on PET-CT and may facilitate this diagnosis.

To study the concordance between the PET-CT pattern and the clinical criteria for LATE, we will compare changes in MMSE scores over one year between patients classified as "LATE" or "AD" based on 18F-FDG PET-CT.

03

Conditions studied

  • Alzheimer s Disease
  • TDP-43 Proteinopathies
  • MCI

Browse trials for

Keywords

  • LATE syndrome
  • Alzheimer's Disease
  • prevalence
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of patients who underwent a PET-CT scan between 2020 and 2026 as part of the diagnostic evaluation for neurocognitive disorders at the Geriatric Research Center (CMRR) of the Nancy University Hospital (CHRU)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - An FDG-PET/CT scan at the Nancy University Hospital
  • A neuropsychological evaluation within 6 months of the FDG-PET/CT scan
  • A neuropsychological follow-up 1 year after the initial evaluation

Exclusion criteria

Exclusion Criteria:

  • Lack of follow-up at the Nancy University Hospital (CHRU) or at the Nancy Geriatric Research and Treatment Center (CMRR) for all of these criteria
  • Not enrolled in a social security program
  • Presence of another neurological, neurodevelopmental, or psychiatric condition that could explain the cognitive impairments
  • Refusal to allow the use of the data
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Alzheimer's disease group
  • LATE syndrome group
  • unidentified disease
06

What researchers measure

Primary outcomes

  1. MMSE score

    MMSE score

    Time frame: 1 year

Secondary outcomes

  1. memory score

    memory score on psychometric test

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Wolk DA, Nelson PT, Apostolova L, Arfanakis K, Boyle PA, Carlsson CM, Corriveau-Lecavalier N, Dacks P, Dickerson BC, Domoto-Reilly K, Dugger BN, Edelmayer R, Fardo DW, Grothe MJ, Hohman TJ, Irwin DJ, Jicha GA, Jones DT, Kawas CH, Lee EB, Lincoln K, Maestre GE, Mormino EC, Onyike CU, Petersen RC, Rabinovici GD, Rademakers R, Raman R, Rascovsky K, Rissman RA, Rogalski E, Scheltens P, Sperling RA, Yang HS, Yu L, Zetterberg H, Schneider JA. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy. Alzheimers Dement. 2025 Jan;21(1):e14202. doi: 10.1002/alz.14202. Epub 2025 Jan 14. PubMed 39807681 ↗
  • Ngam PI, Anzai Y, Cliatt Brown CJ, Frost NA, Keown Sorweid M, Thientunyakit T, Minoshima S; Alzheimer's Disease Neuroimaging Initiative. Copathologies of Limbic-Predominant Age-Related TDP-43 Encephalopathy and Alzheimer Disease: [18F]FDG PET Statistical Mapping and Quantitative MRI Volumetry. J Nucl Med. 2026 Apr 1;67(4):621-628. doi: 10.2967/jnumed.125.270614. PubMed 41571430 ↗
  • Nelson, P. T., et al. (2011). "TDP-43 pathology in aging and Alzheimer's disease: a review." Journal of Neuropathology & Experimental Neurology, 70(6), 425-435.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartEst.
Oct 26, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947446
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Oct 26, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 19, 2026

Study contacts

Anna KEARNEY-SCHWARTZ, PhD
Contact
a.kearney-schwartz@chru-nancy.fr
+33383153322
Anaïck BESOZZI, PhD
study director · CHRU Nancy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion